Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Integrating Bioinformatics and Drug Sensitivity Analyses to Identify Molecular Characteristics Associated with Targeting Necroptosis in Breast Cancer and their Clinical Prognostic Significance

Author(s): Chang Zheng, Hanbin Guo, Yongpan Mo and Guowen Liu*

Volume 19, Issue 5, 2024

Published on: 05 October, 2023

Page: [681 - 694] Pages: 14

DOI: 10.2174/1574892819666230831112815

Price: $65

Abstract

Background: Breast cancer accounts for over 1.8 million new cases worldwide annually, and prompt diagnosis and treatment are imperative to prevent mortality. Necroptosis, a form of programmed cell death, is thought to be a critical pathway for cancer cell apoptosis, yet, its relationship with breast cancer progression and molecular mechanisms remains largely unexplored.

Objectives: Our study aims to investigate the molecular characteristics and clinical prognostic value of necroptosis-related genes in breast cancer using a comprehensive approach that involves integrated bioinformatics analysis along with drug sensitivity assessment.

Methods: Transcriptional, clinical, and tumor mutation burden (TMB) data related to breast cancer from the TCGA and GEO databases were integrated, and the necroptosis gene set was downloaded from the GSEA website for analysis. The screening conditions were set as adjusted p < 0.05 and |log2FC(fold change)| > 0.585 to screen for differential expression genes related to breast cancer necroptosis. Survival prognosis analysis was conducted on breast cancer necroptosis genes. Further analysis was conducted on prognosis-related necroptosis genes, including immune infiltration analysis and GO/KEGG enrichment analysis, to explore the potential biological functions and signaling pathway mechanisms of breast cancer necroptosis genes. Drug sensitivity screening was conducted on the prognosis-related necroptosis to identify potential drugs that target the promotion of necroptosis gene expression, and ultimately, single-gene analysis was performed on the core target genes obtained.

Results: Through integrated bioinformatics analysis, 29 differentially expressed mRNAs related to BRCA-Necroptosis were identified, including 18 upregulated mRNAs and 11 downregulated mRNAs. In addition, single-factor analysis of differential genes showed that the expression of HSPA4, PLK1, TNFRSF1B, FLT3, and LEF1 was closely related to BRCA survival prognosis. Based on the expression of these genes, a breast cancer prognosis model was constructed, and it was found that the area under the curve (AUC) of the curve of the risk genes for necroptosis was the largest, indicating that these genes have a certain clinical predictive significance for the occurrence and prognosis of BRCA. Additionally, there were significant differences in clinical characteristics of BRCA patients with different necroptosis gene expressions. Furthermore, GSVA and immune infiltration analysis revealed that Necroptosis-DEGs mainly affect the occurrence and progression of BRCA by participating in immune functions such as APC co-inhibition, APC costimulation, CCR, checkpoint, as well as infiltrating immune cells such as B cells naive, plasma cells, and T cells CD8. Moreover, the necroptosis gene group column chart indicated a 1-year survival rate of 0.979, a 3-year survival rate of 0.883, and a 5-year survival rate of 0.774. The necroptosis gene group and column chart are important indicators for evaluating BRCA prognosis. Finally, drug sensitivity screening of BRCA-Necroptosis genes showed that compounds such as A- 770041, AC220, AP-24534, Bexarotene, and BMS-509744 have certain effects as potential targeted drugs for the treatment of BRCA necroptosis genes.

Conclusion: Necroptosis genes are implicated in the pathogenesis and progression of breast cancer and are thought to impact the prognosis and response to drug treatments in individuals with BRCA. Consequently, understanding the role of these genes in breast cancer may aid in identifying more precise and efficacious therapeutic targets.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 2017; 3(9): 1228-36.
[http://dx.doi.org/10.1001/jamaoncol.2016.6326] [PMID: 28152151]
[3]
Chow CYC, Lie EF, Wu CH, Chow LWC. Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers. Front Oncol 2022; 12: 964824.
[http://dx.doi.org/10.3389/fonc.2022.964824] [PMID: 36387174]
[4]
Fang F, Mo L, Pan X, et al. DNAJB4 promotes triple-negative breast cancer cell apoptosis via activation of the Hippo signaling pathway. Discover Oncol 2023; 14(1): 40.
[http://dx.doi.org/10.1007/s12672-023-00645-y] [PMID: 37012515]
[5]
Ibrahim A, Toss MS, Atallah NM, Al Saleem M, Green AR, Rakha EA. Combined proliferation and apoptosis index provides better risk stratification in breast cancer. Histopathology 2023; 82(7): 1029-47.
[http://dx.doi.org/10.1111/his.14887] [PMID: 36779253]
[6]
Mohamed HRH, Ibrahim MMH, Diab A. Induction of oxidative DNA damage, cell cycle arrest and p53 mediated apoptosis by calcium titanate nanoparticles in MCF-7 breast cancer cells. Cancer Cell Int 2022; 22(1): 355.
[http://dx.doi.org/10.1186/s12935-022-02780-y] [PMID: 36376858]
[7]
Holmgren C, Sunström Thörnberg E, Granqvist V, Larsson C. Induction of breast cancer cell apoptosis by trail and smac mimetics: Involvement of RIP1 and cFLIP. Curr Issues Mol Biol 2022; 44(10): 4803-21.
[http://dx.doi.org/10.3390/cimb44100327] [PMID: 36286042]
[8]
Chen X, He W, Hu L, et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res 2016; 26(9): 1007-20.
[http://dx.doi.org/10.1038/cr.2016.100] [PMID: 27573174]
[9]
Zhu F, Zhang W, Yang T, He S. Complex roles of necroptosis in cancer. J Zhejiang Univ Sci B 2019; 20(5): 399-413.
[http://dx.doi.org/10.1631/jzus.B1900160] [PMID: 31090266]
[10]
Dillon CP, Green DR. Molecular cell biology of apoptosis and necroptosis in cancer. Adv Exp Med Biol 2016; 930: 1-23.
[http://dx.doi.org/10.1007/978-3-319-39406-0_1] [PMID: 27558815]
[11]
Gong L, Huang D, Shi Y, Liang Z, Bu H. Regulated cell death in cancer: From pathogenesis to treatment. Chin Med J 2022; 136(6): 653-65.
[http://dx.doi.org/10.1097/CM9.0000000000002239] [PMID: 35950752]
[12]
Qin X, Ma D, Tan Y, Wang H, Cai Z. The role of necroptosis in cancer: A double-edged sword? Biochim Biophys Acta Rev Cancer 2019; 1871(2): 259-66.
[http://dx.doi.org/10.1016/j.bbcan.2019.01.006] [PMID: 30716362]
[13]
Liu Z, Choksi S, Kwon HJ, Jiao D, Liu C, Liu Z. Tumor necroptosis-mediated shedding of cell surface proteins promotes metastasis of breast cancer by suppressing anti-tumor immunity. Breast Cancer Res 2023; 25(1): 10.
[http://dx.doi.org/10.1186/s13058-023-01604-9] [PMID: 36703228]
[14]
Xu Y, Wu Q, Tang Z, et al. Comprehensive analysis of necroptosis-related genes as prognostic factors and immunological biomarkers in breast cancer. J Pers Med 2022; 13(1): 44.
[http://dx.doi.org/10.3390/jpm13010044] [PMID: 36675706]
[15]
Hänzelmann S, Castelo R, Guinney J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 2013; 14(1): 7.
[http://dx.doi.org/10.1186/1471-2105-14-7] [PMID: 23323831]
[16]
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12(5): 453-7.
[http://dx.doi.org/10.1038/nmeth.3337] [PMID: 25822800]
[17]
Gaudet P, Škunca N, Hu JC, Dessimoz C. Primer on the Gene Ontology. Methods Mol Biol 2017; 1446: 25-37.
[http://dx.doi.org/10.1007/978-1-4939-3743-1_3] [PMID: 27812933]
[18]
Yu G, Wang LG, Han Y, He QY. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012; 16(5): 284-7.
[http://dx.doi.org/10.1089/omi.2011.0118] [PMID: 22455463]
[19]
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 2017; 45(D1): D353-61.
[http://dx.doi.org/10.1093/nar/gkw1092] [PMID: 27899662]
[20]
Wang W, Tian B, Xu X, et al. Clinical features and prognostic factors of breast cancer in young women: A retrospective single-center study. Arch Gynecol Obstet 2022; 307(3): 957-68.
[http://dx.doi.org/10.1007/s00404-022-06670-6] [PMID: 35835921]
[21]
Valcarcel B, Torres-Roman JS, Enriquez-Vera D, De-la-Cruz-Ku G. Clinical features and outcomes of triple-negative breast cancer among latin american adolescents and young adults compared to middle-aged and elder females: A cohort analysis over 15 years. J Adolesc Young Adult Oncol 2023; jayao.2022.0075.
[http://dx.doi.org/10.1089/jayao.2022.0075] [PMID: 36791318]
[22]
Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC). J Clin Med 2023; 12(4): 1524.
[http://dx.doi.org/10.3390/jcm12041524] [PMID: 36836059]
[23]
Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin 2022; 72(6): 524-41.
[http://dx.doi.org/10.3322/caac.21754] [PMID: 36190501]
[24]
Gu Y, Liu Y, Fu L, et al. Tumor-educated B cells selectively promote breast cancer lymph node metastasis by HSPA4-targeting IgG. Nat Med 2019; 25(2): 312-22.
[http://dx.doi.org/10.1038/s41591-018-0309-y] [PMID: 30643287]
[25]
Chen Y, You Y, Wu Q, et al. Performance of a PLK1 ‐based immune risk model for prognosis and treatment response prediction in breast cancer. Cancer Med 2023; 12(9): 11020-39.
[http://dx.doi.org/10.1002/cam4.5813] [PMID: 36951624]
[26]
Xu F, Zhou G, Han S, et al. Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women. PLoS One 2014; 9(7): e101138.
[http://dx.doi.org/10.1371/journal.pone.0101138] [PMID: 25010932]
[27]
Chen R, Wang X, Fu J, Liang M, Xia T. High FLT3 expression indicates favorable prognosis and correlates with clinicopathological parameters and immune infiltration in breast cancer. Front Genet 2022; 13: 956869.
[http://dx.doi.org/10.3389/fgene.2022.956869] [PMID: 36159964]
[28]
Blazquez R, Rietkötter E, Wenske B, et al. LEF1 supports metastatic brain colonization by regulating glutathione metabolism and increasing ROS resistance in breast cancer. Int J Cancer 2020; 146(11): 3170-83.
[http://dx.doi.org/10.1002/ijc.32742] [PMID: 31626715]
[29]
Meng Y, Zhou J, Liu X, et al. CXC Chemokine receptor type 4 antagonistic gold nanorods induce specific immune responses and long-term immune memory to combat triple-negative breast cancer. ACS Appl Mater Interfaces 2023; 15(15): 18734-46.
[http://dx.doi.org/10.1021/acsami.3c03130] [PMID: 37017641]
[30]
Duan Z, Zhang J, Ye S, et al. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer 2014; 14(1): 681.
[http://dx.doi.org/10.1186/1471-2407-14-681] [PMID: 25236161]
[31]
Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One 2013; 8(8): e71266.
[http://dx.doi.org/10.1371/journal.pone.0071266] [PMID: 23967177]
[32]
Moore AS, Faisal A, de Castro DG, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia 2012; 26(7): 1462-70.
[http://dx.doi.org/10.1038/leu.2012.52] [PMID: 22354205]
[33]
Thomas PS, Patel AB, Lee JJ, et al. Phase i dose escalation study of topical bexarotene in women at high risk for breast cancer. Cancer Prev Res 2023; 16(1): 47-55.
[http://dx.doi.org/10.1158/1940-6207.CAPR-22-0210] [PMID: 36228112]
[34]
Li H, Wang C, Ma P, et al. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway. J Dermatol Sci 2020; 97(3): 208-15.
[http://dx.doi.org/10.1016/j.jdermsci.2020.01.013] [PMID: 32165081]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy